{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Clavreul A"],"funding":["Cancéropôle Grand Ouest","French National Cancer Institute","GIS IBiSA","Ligue Nationale Contre le Cancer"],"pagination":["5510"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9688811"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(22)"],"pubmed_abstract":["Safe maximal resection followed by radiotherapy plus concomitant and adjuvant temozolomide (TMZ) is universally accepted as the first-line treatment for glioblastoma (GB), but no standard of care has yet been defined for managing recurrent GB (rGB). We used the French GB biobank (FGB) to evaluate the second-line options currently used, with a view to defining the optimal approach and future directions in GB research. We retrospectively analyzed data for 338 patients with de novo isocitrate dehydrogenase (IDH)-wildtype GB recurring after TMZ chemoradiotherapy. Cox proportional hazards models and Kaplan-Meier analyses were used to investigate survival outcomes. Median overall survival after first surgery (OS1) was 19.8 months (95% CI: 18.5-22.0) and median OS after first progression (OS2) wa"],"journal":["Cancers"],"pubmed_title":["Management of Recurrent Glioblastomas: What Can We Learn from the French Glioblastoma Biobank?"],"pmcid":["PMC9688811"],"funding_grant_id":["NA","INCA_6298"],"pubmed_authors":["Caire F","Le Reste PJ","Quillien V","Dehais C","Sanson M","Loiseau H","Mokhtari K","Di Stefano AL","Bergemer-Fouquet AM","Gele P","Graillon T","Marguet F","Faisant M","Almairac F","Lantuejoul S","Yordanova Y","Horodyckid C","Gaillard S","Emery E","Desenclos C","Constans JM","Rigau V","Rousseau A","Zemmoura I","Dufay N","Lemee JM","Bonnin A","Frenel JS","Loussouarn D","Autier L","Rousseau N","Burel-Vandenbos F","Meyronet D","Gay E","Rech F","Labrousse F","Feuillard J","Cornu P","Bourg V","Gauchotte G","Blanchet O","Bouillot-Eimer S","Ricard D","Collaborators of the FGB network","Aubriot-Lorton MH","Pallud J","Guilain N","Lippert E","Fermeaux V","Herpe YE","Voirin J","Reyns N","Network F","Boone M","Ghaleh B","Ducray F","Dufour H","Hoang-Xuan K","Seizeur R","Chinot O","Menei P","Guyotat J","Langlois O","Figarella-Branger D","Metellus P","Mossuz P","Chiforeanu DC","Marniche A","Lerintiu F","Niel P","Soulard G","Maurage CA","Delattre JY","Kerdraon O","Turlin B","Herault O","Blonski M","Augereau P","Heller R","Goze C","Mosnier JF","Tebbakha R","Varlet P","Quintin-Roue I","Ahle G","Quillard-Muraine M","Dubus P","Villa C","Farah W","Clavreul A","Bauchet L"],"additional_accession":[]},"is_claimable":false,"name":"Management of Recurrent Glioblastomas: What Can We Learn from the French Glioblastoma Biobank?","description":"Safe maximal resection followed by radiotherapy plus concomitant and adjuvant temozolomide (TMZ) is universally accepted as the first-line treatment for glioblastoma (GB), but no standard of care has yet been defined for managing recurrent GB (rGB). We used the French GB biobank (FGB) to evaluate the second-line options currently used, with a view to defining the optimal approach and future directions in GB research. We retrospectively analyzed data for 338 patients with de novo isocitrate dehydrogenase (IDH)-wildtype GB recurring after TMZ chemoradiotherapy. Cox proportional hazards models and Kaplan-Meier analyses were used to investigate survival outcomes. Median overall survival after first surgery (OS1) was 19.8 months (95% CI: 18.5-22.0) and median OS after first progression (OS2) wa","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-26T05:17:18.194Z","creation":"2025-04-06T11:29:10.272Z"},"accession":"S-EPMC9688811","cross_references":{"pubmed":["36428604"],"doi":["10.3390/cancers14225510"]}}